scholarly journals Multi-omic Single-Shot Technology for Integrated Proteome and Lipidome Analysis

2020 ◽  
Author(s):  
Yuchen He ◽  
Edrees Rashan ◽  
Vanessa Linke ◽  
Evgenia Shishkova ◽  
Alexander Hebert ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Single Shot ◽  
Metabolome Analysis ◽  
Lipidome Analysis

Abstract Mass spectrometry (MS) serves as the centerpiece technology for proteome, lipidome, and metabolome analysis. Despite the versatility of MS systems, fractured methodology drives nearly all MS laboratories to specialize in analysis of a single ome at the exclusion of the others. We describe a technology to achieve broad and deep coverage of multiple molecular classes simultaneously through multi-omic single-shot technology (MOST) requiring only one column, one LC-MS instrument and a simplified workflow.

scholarly journals Multi-Omic Single-Shot Technology for Integrated Proteome and Lipidome Analysis

2021 ◽  
Vol 93 (9) ◽  
pp. 4217-4222 ◽  
Author(s):  
Yuchen He ◽  
Edrees H. Rashan ◽  
Vanessa Linke ◽  
Evgenia Shishkova ◽  
Alexander S. Hebert ◽  
...  
Keyword(s):  
Single Shot ◽  
Lipidome Analysis

scholarly journals Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Cells ◽  
2018 ◽  
Vol 8 (1) ◽  
pp. 14 ◽  
Author(s):  
Shin-Ichi Ueno ◽  
Shinji Saiki ◽  
Motoki Fujimaki ◽  
Haruka Takeshige-Amano ◽  
Taku Hatano ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Severity ◽  
Rating Scale ◽  
Statistical Significance ◽  
Experimental Studies ◽  
Time Of Flight ◽  
Metabolome Analysis ◽  
Flight Mass Spectrometry

Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD.

Sign in / Sign up

Export Citation Format

Share Document